Literature DB >> 22725831

Overdose with levetiracetam: a case report and review of the literature.

T M Larkin1, A N Cohen-Oram, G Catalano, M C Catalano.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Levetiracetam is an anticonvulsant agent that was first approved for use in the United States in 1999 and has a maximum recommended adult dose of 3000 mg daily. It has been noted to have a relatively mild adverse effect profile, with the most common side effects being somnolence, asthenia, infection, and dizziness. Although it has been widely prescribed, there have been few reports on the safety of this agent in overdose. CASE
SUMMARY: We present the case of a 49-year-old man who ingested over 22 500 mg of levetiracetam in a suicide attempt. The patient arrived at the Emergency Department 6·5 h after the ingestion and was noted to have no significant sequelae from the ingestion. Based on the patient's weight, he ingested 358 mg/kg of levetiracetam. WHAT IS NEW AND
CONCLUSION: The few cases of levetiracetam overdose reported in the literature were associated with relatively mild, if any, symptoms. However, one patient who overdosed on levetiracetam became obtunded and developed significant respiratory distress that required intubation and ventilatory support. Therefore, clinical vigilance is still required in the cases of levetiracetam overdose.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725831     DOI: 10.1111/j.1365-2710.2012.01361.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  A case of mycosis fungoides-like lesions developing after levetiracetam therapy.

Authors:  İbrahim Bora; Aylin Bican Demir; Emel Bülbül Başkan; Şaduman Balaban
Journal:  Epilepsy Behav Case Rep       Date:  2014-10-25

2.  Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma.

Authors:  Roberta Sulsenti; Barbara Frossi; Lucia Bongiovanni; Valeria Cancila; Paola Ostano; Irene Fischetti; Claudia Enriquez; Francesca Guana; Giovanna Chiorino; Claudio Tripodo; Carlo E Pucillo; Mario P Colombo; Elena Jachetti
Journal:  Front Immunol       Date:  2021-03-02       Impact factor: 7.561

3.  Multifocal myoclonus as a presentation of levetiracetam toxicity.

Authors:  Mei Bou Nasif; Shweta Varade; Mohamad Z Koubeissi
Journal:  Clin Neurophysiol Pract       Date:  2021-11-07

4.  Levetiracetam poisoning with acute kidney injury treated with hemodialysis: A case report.

Authors:  Hiraku Sedogawa; Norihiro Watanabe; Yoshikazu Hirose; Naoko Mizouchi; Shunri Shimagaki; Hiroki Yamaguchi; Yasuo Hirose
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

5.  Correlation of elevated lamotrigine and levetiracetam serum/plasma levels with toxicity: A long-term retrospective review at an academic medical center.

Authors:  Kelly E Wood; Kendra L Palmer; Matthew D Krasowski
Journal:  Toxicol Rep       Date:  2021-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.